Dr. Reddy's Laboratories Limited has informed the Exchange regarding Board meeting held on May 09, 2025.

Revenue growth above 20%EBITDA margin expansionResults restatedRelated-party transactionsContingent liabilities increasedResults View source PDF Explain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.1%Reaction day

₹1158.09

prior close

₹1155.90

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+3.9%-0.8% vs market

Pharmaceuticals peers, median of 148sector+2.8%+0.3% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty 100 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

+0.3

15m

+0.2

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.1+3.9-0.8+2.8+0.3

Next day

+4.3+2.7+1.7+4.2+0.1

+5.4+3.1+2.3+5.3+0.1

+6.3+4.6+1.6+5.5+0.8

+6.1+4.7+1.4+6.3-0.2

+5.0+4.6+0.4+7.2-2.2

+5.8+4.0+1.8+6.4-0.7

15d

+7.9+3.7+4.2+7.1+0.8

+17.1+4.4+12.7+8.7+8.4

+8.1+5.3+2.8+11.2-3.1

+5.2+2.7+2.6+6.0-0.7

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr. Reddy's reported Q4FY25 consolidated revenue of Rs. 85,060 Mn, up 20% YoY (12% underlying, excluding the newly acquired NRT business), and FY25 revenue of Rs. 325,535 Mn, up 17% YoY. Profit after tax (attributable to equity holders) rose 22% YoY to Rs. 15,939 Mn in Q4 but only 2% YoY to Rs. 56,544 Mn for the full year. EBITDA margin expanded to 29.1% in Q4 from 26.4% a year earlier. The Board recommended a final dividend of Rs. 8 per share (record date July 10, 2025) and re-appointed G V Prasad as Co-Chairman & MD for another 5 years from January 30, 2026. The company received an unmodified audit opinion, and the new NRT (Haleon) and Nestle nutraceuticals businesses contributed meaningfully to the year's growth.

Likely market impact

Strong Q4 print and the dividend signal are positive for shareholders, but the modest 2% full-year PAT growth and the ongoing US FCPA investigation are watchpoints. Leadership continuity and a clean audit opinion should support sentiment.